The application discloses that ER-negative breast cancers can be converted into ER positive breast cancers, such as to a breast cancer of luminal-like phenotype by treatment with anti-PDGF-CC antibodies. ER-positive breast cancers, including luminal-like breast cancers can be treated with anti-...
10 Toi M, Imoto S, Ishida T, et al. Adjuvant S-1 plus endocrine therapy for oestrogen receptor-positive, HER2-negative, primary breast cancer: a multicentre, open-label, randomised, controlled, phase 3 trial. Lancet Oncol. 2021...
1.Systemic Therapy for Estrogen Receptor–Positive, HER2-Negative Breast Cancer. N Engl J Med 2020;383:2557-70.DOI: 10.1056/NEJMra1307118. 2.Hitisha K. Patel, et al. Selective estrogen receptor modulators (SERMs) and selective estrogen receptor degra...
D.; Stepien, P.; Feit, A.S.; Bergholz, J.; Michowski, W.; Otto, T.; et al. Increased Lysosomal Biomass Is Responsible for the Resistance of Triple-Negative Breast Cancers to CDK4/6 Inhibition. Sci. Adv. 2020, 6, eabb2210. ...
response and cell cycle progression6,7. Patients with ER-negative breast cancer tend to have a poorer prognosis than those with ER-positive breast cancer8. However, the network of underlying regulatory mechanisms in the initiation and progression of ER-negative breast cancer remains poorly understood...
In the case of advanced disease where two other drugs have been tried, the antibody-drug conjugatesacituzumab govitecan(Trodelvy) may be tried. Get an overview ontriple-negative breast cancer symptoms and treatment.
Third-generation aromatase inhibitors (AIs; anastrozole, letrozole, exemestane) have replaced tamoxifen as the adjuvant treatment of choice for postmenopau... AM Brufsky - 《Clinical Breast Cancer》 被引量: 135发表: 2007年 Chemoprevention of Hormone Receptor-Negative Breast Cancer: New Approaches Nee...
Background: The everolimus–exemestane pair was approved by the US Food and Drug Administration (FDA) in 2012 to treat women with hormone receptor-positive (ER+), HER2-negative metastatic breast cancer (MBC) that got worse after treatment with aromatase inhibitor alone. The main benefit of this...
negativity were independent predictors of shorter RFS. TN breast cancer had a higher relapse rate and more aggressive clinicopathological characteristics than non-TN in node-negative breast cancer. Thus, TN breast cancer should be integrated into risk factor analysis for node-negative breast cancer. ...
Estrogen receptor-positive/human epidermal growth factor receptor 2-negative breast cancer (ER+/HER2− breast cancer)breast-conserving treatment (BCT)axillary surgerypostmenopausal womenlymph node metastasisBackground: Previous clinical trials have diminished the significance of lymph node (LN) metastasis ...